Novel therapeutics targeting oncogenic viruses
Who We Are
Our team is comprised of industry leaders with decades of experience in early stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials.
What We’re Doing
Toragen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers.
Where We’re Going
Toragen is preparing to initiate a Phase I clinical trial with its lead compound in HPV-associated malignancies and is seeking investor funding for research and development.